- **TITLE:** The emergence of SARS-CoV-2 lineages and associated antibody responses among
 asymptomatic individuals in a large university community
- 3
- AUTHORS & AFFILIATIONS: Marlena R. Merling ¹, Amanda Williams ^{1,2}, Najmus Mahfooz ¹,
 Marisa Ruane-Foster ¹, Jacob Smith ², Jeff Jahnes ², Leona W. Ayers ³, Jose A. Bazan ⁴, Alison
 Norris ^{4,5}, Abigail Norris Turner ⁴, Michael Oglesbee ², Seth A. Faith ², Mikkel B. Quam ⁵, *, Richard
 T. Robinson^{1, *}
- 8
- ¹ Department of Microbial Infection & Immunity, The Ohio State University, Columbus, OH, USA
- ² Infectious Disease Institute, The Ohio State University, Columbus, OH, USA
- ³ Department of Pathology, The Ohio State University, Columbus, OH, USA
- ⁴ Division of Infectious Disease, Department of Internal Medicine, The Ohio State University,
- 13 Columbus, OH, USA
- ⁵ Department of Epidemiology, The Ohio State University, Columbus, OH, USA
- 15 * Co-corresponding authors

16 ABSTRACT

17 SARS-CoV-2 (CoV2) infected, asymptomatic individuals are an important contributor to COVID 18 transmission. CoV2-specific immunoglobulin (Ig)—as generated by the immune system following 19 infection or vaccination-has helped limit CoV2 transmission from asymptomatic individuals to 20 susceptible populations (e.g. elderly). Here, we describe the relationships between COVID 21 incidence and CoV2 lineage, viral load, saliva lg levels (CoV2-specific IgM, IgA and IgG) and 22 inhibitory capacity in asymptomatic individuals between Jan 2021 and May 2022. These data 23 were generated as part of a large university COVID monitoring program and demonstrate that 24 COVID incidence among asymptomatic individuals occurred in waves which mirrored those in 25 surrounding regions, with saliva CoV2 viral loads becoming progressively higher in our community 26 until vaccine mandates were established. Among the unvaccinated, infection with each CoV2 27 lineage (pre-Omicron) resulted in saliva Spike-specific IgM, IgA and IgG responses, the latter 28 increasing significantly post-infection and being more pronounced than N-specific IgG responses. 29 Vaccination resulted in significantly higher Spike-specific IgG levels compared to unvaccinated 30 infected individuals, and uninfected vaccinees' saliva was more capable of inhibiting Spike 31 function. Vaccinees with breakthrough Delta infections had Spike-specific IgG levels comparable 32 to those of uninfected vaccinees; however, their ability to inhibit Spike binding was diminished. 33 These data demonstrate that COVID vaccines achieved hoped-for effects in our community, 34 including the generation of mucosal antibodies that inhibit Spike and lower community viral loads, 35 and suggest breakthrough Delta infections were not due to an absence of vaccine-elicited lg, but 36 instead limited Spike binding activity in the face of high community viral loads.

37 INTRODUCTION

38 Coronaviruses are single-stranded RNA viruses that cause respiratory disease in a range of 39 mammalian hosts. The Coronavirus Disease 2019 (COVID-19, or COVID) pandemic began in 40 December 2019, after transmission of a novel coronavirus to an individual living in China. The 41 sequence homology of this novel coronavirus to severe acute respiratory syndrome associated 42 coronavirus (SARS-CoV) led to its being named SARS-CoV-2 (CoV2). CoV2 spreads via aerosol 43 and respiratory droplets, causing either an asymptomatic infection or a flu-like illness that affects 44 multiple organ systems and presents as fever, cough, dyspnea, malaise, delirium and death. 45 International spread of CoV2 was rapid, and by February 2020 it had spread to nearly every 46 country in the world (1). Now, 3 years after its emergence, CoV2 is estimated to have infected 47 ~630 million individuals and killed >6.5 million individuals worldwide (2). The United States has 48 reported more deaths than any other country (2).

49

50 Viruses mutate to varying degrees depending on the nature of their genome and the proofreading 51 activity (or lack thereof) of associated polymerases. CoV2 is no exception to this, and within a 52 year of its emergence multiple lineage variants of concern (VOCs) appeared in numerous 53 countries. B.1.1.7 (now called Alpha) and B.1.351 (now called Beta) were the first VOCs to be 54 identified in September 2020 (Alpha, in United Kingdom) and October 2020 (Beta, in South 55 Africa), and contained numerous missense mutations affecting the Spike protein (3, 4). The Spike 56 protein is essential for CoV2 infection of target cells and contains a receptor-binding domain 57 (RBD) which recognizes and binds the host receptor angiotensin-converting enzyme 2 (ACE2) 58 (5). The Alpha and Beta lineage RBD mutations lead to tighter Spike: ACE2 structural interactions 59 (6) and increased the transmissibility of CoV2 (7, 8). In January 2021, the P.1. (now called 60 Gamma) lineage was reported in Brazil to contain even more missense mutations in more genes, 61 including Spike (9). As with Alpha, the mutations inherent to the Gamma lineage increased its 62 transmissibility (9). Two additional lineages emerged in March 2021 and November 2021,

respectively, and in time would supplant all prior lineages in the speed with which they spread: the Delta lineage, which was first reported in India (*10*), and the Omicron lineage, reported in southern Africa (*11*). CoV2 continues to evolve, and deaths due to COVID continue to cause overall declines in life expectancy for many countries, including the United States (*12, 13*).

67

68 After previous coronavirus disease outbreaks, such as those caused by SARS-CoV and Middle 69 East respiratory syndrome coronavirus (MERS-CoV), animal models and other experimental 70 systems demonstrated that coronavirus-specific antibodies are generated soon after infection (14. 71 15), and can block viral entry by interfering with the Spike:ACE2 interaction (16-21). In the upper 72 respiratory tract and oral cavity, antibodies are generated by B cells in mucosa-associated 73 lymphoid tissue (MALT) and regional draining lymph nodes, typically within several days of 74 antigen encounter, and comprise several isotypes (IgM, IgA and IgG) which differ in their secretion 75 kinetics and effector mechanism. IgM is often the first isotype to appear following antigen 76 exposure, and eliminates viruses by precipitating the membrane attack complex on virus-infected 77 cells (i.e. the classical complement pathway). In the context of CoV2 infection, however, IqA 78 dominates the early neutralizing antibody response at mucosal sites (22). IgA, a weak inducer of 79 the complement pathway, protects mucosal sites by blocking and sterically hindering antigen 80 interaction with the epithelial surface, trapping it in mucus which is eventually cleared via 81 peristalsis. IgG is often the last isotype to appear following antigen exposure but is the most 82 versatile in terms of effector mechanisms and durability, as the B cells which produce IgG can 83 become plasma cells that reside in bone marrow and continuously secrete IgG for months to 84 years.

85

The fact that coronavirus-specific Ig is secreted following natural infection, long-lived, and able to disrupt Spike:ACE2 interactions are the foundations on which multiple monitoring, therapeutic and vaccine strategies against CoV2 have been built. Prior to mass PCR testing, CoV2-reactive

89 Ig in sera was the only biomarker for monitoring CoV2 prevalence at a population level (23). The 90 discovery that plasma of COVID-convalescent individuals contains polyclonal Ig with CoV2-91 neutralizing activity (24) paved the way for multiple clinical trials testing the efficacy of 92 convalescent plasma therapy against COVID (25). Whether convalescent plasma therapy was 93 efficacious remains debated (26). What is not debated, however, is the efficacy of vaccines which 94 were designed to elicit Ig against CoV2. In the US, the first COVID vaccines available comprised 95 either a two-dose encapsulated mRNA formulation (BNT162b2 or mRNA-1273) or a single-dose 96 adenovirus vector formulation (Ad26.COV2.S). The US Food & Drug Administration (FDA) 97 granted emergency use authorizations (EUA) for BNT162b2 and mRNA-1273 on Dec 11 2020 98 and Dec 18 2020, respectively (27, 28); the FDA EUA for Ad26.COV2.S was granted on Feb 27 99 2021 (29). The advent of these and other COVID vaccines led to dramatic declines in COVID 100 morbidity and mortality (30), and-relative to vaccinated individuals-unvaccinated individuals 101 are more likely to need hospitalization or die following CoV2 infection (31).

102

103 Since interrupting the Spike: ACE2 interaction was the goal of now-approved vaccines (32, 33). 104 and remains a goal of potential COVID therapies (34, 35), the continual emergence of new CoV2 105 lineages with numerous and diverse Spike mutations threatens our ability to prevent and treat 106 future CoV2 infections. It is therefore important to understand the relationships between CoV2 107 lineage emergence, CoV2-specific lg levels-as elicited by either natural infection or 108 vaccination—and their neutralization capacity. This is especially true of asymptomatic individuals 109 who are PCR positive (PCR^{POS}), as they are estimated to account for 50-65% of all transmission 110 (36, 37). Here, we describe the relationships between COVID incidence, CoV2 lineage, viral load, 111 CoV2-specific Ig responses (IgM, IgA & IgG) and inhibitory capacity in the saliva of asymptomatic PCR^{POS} individuals, as the oral cavity and saliva-in addition to being readily accessible-are 112 113 important sites of CoV2 infection and transmission (38) (especially newer Omicron variants (39-43)). CoV2-specific lq responses were similarly assessed in PCR^{NEG} individuals with a history of 114

- 115 CoV2 infection and/or COVID vaccination with pre-Omicron vaccines. These data were generated
- as part of a large university COVID monitoring program which occurred between Aug $2020 \rightarrow$ Jun
- 117 2022.

118 METHODS

119

Institutional approval statement. This work was reviewed and approved by The Ohio State University Biomedical Sciences Institutional Review Board (ID #2021H0080). This work was also reviewed and approved by the Ohio State Institutional Biosafety Committee (IBC) (ID #2020R00000046).

124

125 Saliva specimen collection and handling. The Ohio State COVID monitoring program was 126 active from Aug 2020 through June 2022. As part of this program, saliva specimens were collected 127 on a weekly basis from students, staff and faculty who self-reported as being asymptomatic at the 128 time of specimen collection. On and prior to the day of saliva collection at one of several mass 129 testing sites (FIG 1A), individuals were instructed to define themselves symptomatic if they had 130 at least one or more of the following : fever, chills, shortness of breath, difficulty breathing, fatigue, 131 muscle aches, body aches, headache, new loss of taste, new loss of smell, sore throat, 132 congestion, runny nose, nausea, vomiting, or diarrhea. To prevent contagion, symptomatic 133 individuals were instructed not to come to the mass testing site and were instead referred to a 134 healthcare provider for follow-up (e.g. the campus student health clinic). Individuals were defined 135 as asymptomatic if they had none of the symptomatic conditions listed above. On the day of 136 testing, individuals were instructed to refrain from food or drink for 30 minutes prior to collection, 137 and to gently eject saliva into the collection tube, swallowing first and keeping saliva free from 138 mucus, until the 1 mL mark on a sterile conical was reached (i.e. passive drool method). 139 Specimens from asymptomatic individuals were collected at each of the six Ohio State campuses 140 in Franklin county (OSU-Columbus), Licking county (OSU-Newark), Richland county (OSU-141 Mansfield), Allen county (OSU-Lima), Marion county (OSU-Marion) and Wayne county (OSU-142 Wooster). Specimens were then couriered to the CLIA-approved Applied Microbiology Services 143 Lab (AMSL) of the Ohio State Infectious Disease Institute (IDI) and analyzed in accordance with

144 the SalivaDirect assay, a clinical diagnostic test that is Emergency Use Authorization (EUA) 145 approved by the US Food & Drug Administration (FDA) for SARS-COV-2 detection (44). While 146 performing the SalivaDirect real time polymerase chain reaction (PCR), saliva samples were 147 stored in a 4°C cold room until they were deemed either PCR negative (PCR^{NEG}) or PCR positive 148 (PCR^{POS}) for CoV2. Per the SalivaDirect method (45), any sample with a C_T value \leq 40 was considered PCR^{POS} for CoV2. The positive or negative status of the sample was reported to the 149 150 individual and regional public health authorities (Columbus Public Health, Ohio Department of 151 Health, ODH,) per state and federal policies at the time. PCR^{POS} saliva samples and select PCR^{NEG} saliva samples were then removed from the 4°C cold room, aliquoted into microcentrifuge 152 153 tubes, frozen (-20°C) and analyzed for viral genome sequencing and lineage identification, as 154 well as host antibody response characterization.

155

Sequencing and Lineage Identification: PCR^{POS} saliva samples with a $C_T \le 33$ had their whole 156 157 CoV2 viral genome sequenced and lineage assigned per the methods described in our previous 158 work (46) (samples with a $C_T > 33$ had insufficient viral RNA for sequencing). CoV2 genome copy 159 numbers were calculated via linear regression analysis, by comparison to the C_T values of 160 SalivaDirect reference standards. CoV2 genome sequences were submitted to the Global 161 Initiative on Sharing Avian Influenza Data (GISAID) database in a manner consistent with ODH 162 expectations and policies at that time, in as close to real time as possible. The abbreviations we use for each lineage in this study and associated figures are as follows: CoV2^{Anc}, the ancestral 163 164 lineage of CoV2 which emerged from Wuhan, China; CoV2^{US}, the B.1.2 lineage which was among 165 the first detected in our region of the United States (46-48); CoV2^{Alpha}, the B.1.1.7 lineage or Alpha variant of concern (VOC) which was first reported by the UK in Dec 2020 (3); CoV2^{Beta}, the B.1.351 166 lineage or Beta VOC which was first reported in South Africa in Dec 2020 (4); CoV2^{Gamma}. the P.1 167 168 lineage or Gamma VOC which was first reported in Brazil in Jan 2021 (9); CoV2^{Delta}, the B.1.617.2

lineage or Delta VOC which was first reported in India in Dec 2020 (10); CoV2^{Omicron}, the B.1.1.529 lineage or Omicron VOC which was first reported in South Africa in Nov 2021 (11); CoV2^{O-BA.1}, the BA.1 variant of CoV2^{Omicron}; CoV2^{O-BA.2}, the BA.2 variant of CoV2^{Omicron}; CoV2^{O-BA.4}, the BA.4 variant of CoV2^{Omicron}; CoV2^{O-BA.5}, the BA.2 variant of CoV2^{Omicron}. The nonsynonymous Spike mutations which distinguish these lineages are depicted in supplemental **FIG S1**. Any lineage which was not a VOC or otherwise not mentioned above (e.g. Epsilon) is labeled "Non-VOC."

176

177 **COVID wave designations and comparisons.** We defined a COVID wave within our university 178 community as when new PCR^{POS} case counts rose above the overall period median for \geq 3 weeks 179 in a row (the overall period being Jan 2021 through Jun 2022). For comparisons to COVID 180 incidence in surrounding counties, we accessed publicly available ODH data via their public-181 facing dashboard (accessed Nov 14 2022).

182

183 Measuring Binding Antibody Levels in Saliva: After PCR results were reported (typically within 24 hours of specimen collection), PCR^{POS} and select PCR^{NEG} specimens were removed from the 184 185 4°C cold room, aliguoted into microcentrifuge tubes containing Triton X-100 to inactivate CoV2 (final concentration: 1% Triton X-100) (49). PCR^{NEG} samples were selected based on the donors' 186 187 having had either a prior CoV2 infection (allowing us to measure durability of the antibody 188 response following natural infection) or their having been vaccinated against COVID (allowing us 189 to compare the antibody responses of uninfected vaccinated individuals to those of infected 190 vaccinated individuals, a.k.a. breakthrough infections). All samples were treated identically regardless of whether they were PCR^{POS} or PCR^{NEG}. Following the addition of Triton X-100, 191 192 samples were vortexed and allowed to incubate for 1 hour at room temperature (49). Samples 193 were subsequently stored at -80°C until the antibody levels in all samples could be measured at 194 the same time, thus eliminating batch effects. The Meso Scale Diagnostics (MSD) V-Plex platform

195 was used to measure the concentration of CoV2 antigen specific immunoglobulin (IgM, IgA and/or IaG) in PCR^{POS} and PCR^{NEG} samples. Briefly, the MSD V-Plex assay comprises a 96-well plate 196 197 which, within each well, contains multiple spots that were coated with defined antigens. For our 198 study, these antigens included recombinant forms of three CoV2^{Anc} lineage proteins 199 (Nucleocapsid [N], Spike, and the Spike Receptor Binding Domain [RBD]), as well as CoV2^{Alpha} Spike, CoV2^{Beta} Spike, CoV2^{Gamma} Spike, and CoV2^{Delta} Spike (**FIG S1**). The Spike antigens 200 201 consisted of the trimerized form of the ectodomain; the N antigen consisted of the full-length 202 protein. Antibodies in the sample bind to the antigens, and reporter-conjugated secondary 203 antibodies were used for detection. Saliva samples were thawed on ice and diluted by a factor of 204 10 in the diluent provided in the V-Plex assay kit for each assay. The V-Plex assays were 205 performed according to manufacturer instructions, and plates were read on an MSD instrument 206 which measures light emitted from reporter-conjugated secondary antibodies. Using MSD's 207 analysis software, the light signal measured by the MSD instrument was converted into arbitrary 208 units (AU) representing amount of antibody present relative to the standard curve of the assay. 209 The AU values for IgM, IgA and IgG binding to CoV2^{Anc} N, Spike, and Spike RBD were 210 transformed to WHO binding antibody units (BAU) via validated WHO standards and conversion 211 factors provided by MSD. The AU values for IgM, IgA and IgG binding to other forms of N or Spike 212 (i.e., those of VOC) cannot be converted to WHO BAU, as there are no WHO standards for these 213 recombinant proteins. For this reason, the levels of each Ig isotype which bind to CoV2^{Alpha}, CoV2^{Beta}, CoV2^{Gamma}, and CoV2^{Delta} forms of Spike are expressed as AU. 214

215

Spike inhibition assay. The capacity of saliva specimens to inhibit Spike activity was quantified using a commercially available ACE2 displacement assay (MSD COVID-19 ACE2 Neutralization Kit method). Plate-bound Spike was incubated with diluted saliva (the same specimens used for Ig measurements) per manufacturer protocols, followed by washing and addition of a luminescent probe-conjugated, recombinant form of human ACE2. The extent to which luminescence declined

relative to non-saliva (i.e., diluent only) treated wells was used to derive a percent inhibition value for each individual sample, using the following formula: % inhibition = 1 - (saliva sample luminescence value / diluent only luminescence value) × 100.

224

225 Graphing and statistics. Graphs were generated in RStudio or GraphPad. All statistical tests 226 were performed in RStudio. Data was tested for normality using the Kolmogorov-Smirnov test and 227 for equal variance using the Bartlett test of homogeneity of variances. For data that did not have 228 normal distribution, the Kruskal-Wallis rank sum test was used to determine if there were 229 significant differences between groups in unpaired datasets, and the Friedman rank sum test was 230 used in paired datasets. Within those datasets, the significant differences between groups were 231 identified via an unpaired or paired Wilcoxon rank sum test as appropriate with Benjamini-232 Hochberg p value adjustment method. For the neutralization data which contained several zero 233 values, the Shapiro-Wilk normality test was used, followed by the Bartlett test of homogeneity of 234 variances. The Kruskal-Wallis rank sum test was used to determine if significant differences were 235 present, followed by Dunn's test with Benjamini-Hochberg p value adjustment method to identify 236 which groups were significantly different. Differences between groups were considered significant 237 if P < 0.05 and are graphically indicated by 1 or more asterisks (*P < 0.05; **P < 0.005; ***P < 0.005238 0.0005).

239

Abbreviations. The following abbreviations are used throughout our manuscript: PCR^{POS} , an individual or saliva specimen that was PCR positive for CoV2 (C_T value ≤ 40); PCR^{NEG} , an individual or saliva specimen that was PCR negative for CoV2; **Spike** and **N**, unless otherwise stated the Spike and N proteins of CoV2 (not any other coronavirus); **CoV2-Ig**, immunoglobulin of any isotype that recognizes any CoV2 antigen; **IgM**^{Spike}, IgM that recognizes Spike; **IgA**^{Spike}, IgA that recognizes Spike; **IgG**^{Spike}, IgG that recognizes Spike; **IgG**^{RBD}, IgG that recognizes the

- 246 Spike Receptor Binding Domain; **IgG**^N, IgG that recognizes the N protein; **Vax**^{POS}, an individual
- who was fully vaccinated against COVID (but not boosted) prior to saliva specimen collection;
- 248 Vax^{NEG}, an individual who was not fully vaccinated against COVID prior to saliva specimen
- collection; **New^{POS}**, an individual who at the time of saliva collection was PCR^{POS} for the first time;
- 250 **Prior**^{POS}, an individual who at the time of saliva collection was PCR^{NEG} but who had a prior CoV2
- 251 infection (i.e. the individual had been PCR^{POS} 3-9 months prior).

252 **RESULTS**

253

254 I. Study overview

255

256 The first confirmed cases of COVID in the state of Ohio were reported on Mar 9 2020 (50). The 257 Ohio State University suspended on campus activities the same day (51) and subsequently 258 developed a campus wide plan to monitor the incidence of CoV2 infection among its students, 259 staff and faculty (52). Individuals participating in this monitoring program, which formally began in 260 Aug 2020, provided saliva on a weekly basis for COVID testing. Prior to testing, individuals who 261 self-reported as being symptomatic were not tested and were instead given a clinical referral (see 262 Methods for additional details). Individuals who self-reported as being asymptomatic provided a 263 saliva specimen via a passive drool method at each of our six university campuses (FIG 1A). 264 Specimens were assessed by our CLIA-certified lab for the presence of CoV2 using real-time 265 quantitative reverse transcription PCR (gRT-PCR). Specimens were not pooled prior to testing. 266 gRT-PCR results were reported to the individual and the regional public health authority per state 267 and federal policies at the time. If a specimen had a C_T value ≤ 40 it was considered positive for 268 CoV2 virus (PCR^{POS}). Per our Institutional Review Board (IRB) approved protocols and workflows 269 (FIG 1B), PCR^{POS} saliva samples were subsequently used for CoV2 lineage identification and 270 CoV2-specific immunoglobulin (CoV2-lg) measurements. In some instances, select saliva 271 samples that were negative for CoV2 virus (PCR^{NEG}) were also collected, the reasons for which 272 will be made clear in sections below. The relationships between these molecular and 273 immunological readouts to one another, as well as to coded data concerning the prior infection 274 status and vaccination status of the saliva donor, are described below for the period spanning Jan 275 2021 (before COVID vaccines were widely available to students in our university community) to 276 June 2022, when the monitoring program ended. See Methods for details regarding saliva 277 collection, symptomatic versus asymptomatic designation, qRT-PCR, CoV2 lineage identification,

278 CoV2-Ig measurements, and statistical analyses. In total, >850,000 diagnostic PCR tests were
279 performed by our lab during this monitoring program.

280

II. The incidence of CoV2 positivity in our university community occurred in waves which reflected those occurring in surrounding regions.

283

284 The incidence of new PCR^{POS} cases among asymptomatic individuals in our university 285 community, for the period spanning Jan 2021→June 2022, is shown in **FIG 2**. COVID monitoring 286 occurred before Jan 2021; however, because the bulk of PCR testing at that time was contracted 287 to a commercial entity, our access to the raw PCR data before Jan 2021 is limited. Above these 288 data are two timelines relevant to data interpretation, indicating when Ohio COVID vaccination 289 policies shifted from prioritizing at risk populations (e.g. elderly) to anyone ≥ 16 years of ages well 290 as the deadlines for all our community members (i.e. university students, faculty and staff) to have 291 received their first and second COVID doses (Oct 15 2021 and Nov 15 2021, respectively) (53). 292 Indicated below the data are corresponding intervals in the academic calendar, which will be 293 referred to in subsequent sections. We identified 11,989 PCR^{POS} individuals between Jan 294 2021 \rightarrow June 2022; the median, mean and maximum new PCR^{POS} cases per test day were 15, 34 295 and 523, respectively. There were, however, six time periods when the new case counts rose 296 above the overall period median for \geq 3 weeks in a row. These six time periods are hereafter 297 referred to as Waves 1–6 and spanned the following dates: *Wave 1*, Jan 11 2021 \rightarrow Jan 29 2021; 298 Wave 2, Feb 22 2021→ Mar 12 2021; Wave 3, Mar 22 2021→ Apr 16 2021; Wave 4, Aug 16 299 2021→ Sep 24 2021; Wave 5, Nov 15 2021→ Feb 18 2022; Wave 6, Apr 18 2022→ May 6 2022. 300 The waves of COVID incidence amongst asymptomatic individuals in our university community 301 mirrored (rather than preceded) the waves of COVID incidence in the counties surrounding each 302 university campus (54) (supplemental **FIG S2**).

303

304 III. Prior to community vaccine requirements being established, CoV2 was becoming 305 progressively more concentrated in the saliva of asymptomatic individuals.

306

307 The emergence of CoV2 lineage variants in multiple Ohio communities (55-61) with potential for 308 greater infectivity and/or transmissibility led us to assess the relationship between CoV2 309 abundance in saliva and variant identity. We used the qRT-PCR cycle threshold (C_T) value as a 310 readout of CoV2 abundance, as the SalivaDirect C_T value is inversely proportional to CoV2 viral 311 load (i.e. a lower C_T value corresponds to higher CoV2 RNA levels in the tested sample) (45), and 312 a commonly used as a proxy for probability of transmission (i.e. a lower C_T value correspond to 313 higher transmission probability) (62-66). Variant identity was determined by next generation 314 sequencing of the entire CoV2 genome and subsequent alignment with Global Initiative on 315 Sharing Avian Influenza Data (GISAID) reference sequences. During the entire monitoring period, 316 CoV2 genome sequences were submitted to the GISAID database in a manner consistent with 317 ODH expectations and policies at that time, in as close to real time as possible.

318

319 The weekly composite and daily individual C_T values of each PCR^{POS} individual over this period 320 are shown in FIG 3A and FIG 3B, respectively, with color annotations in FIG 3B indicating the 321 lineage identity. The same data are presented in two ways (weekly composite versus daily 322 individual) in order to best illustrate the following trends: During Wave 1 (Week 2 of Jan 2021 \rightarrow 323 Week 4 of Jan 2021), the median weekly C_T values of all PCR^{POS} saliva samples ranged between 324 29 - 30.5 (FIG 3A). During Wave 2 (Week 4 of Feb 2021 \rightarrow Week 2 of Mar 2021) the median 325 weekly C_T values ranged between 28 - 30.5 (**FIG 3A**). The median C_T range lowered and tightened 326 during Wave 3 (Week 4 of Mar 2021 \rightarrow Week 2 of Apr 2021) median weekly C_T values ranged 327 from 28.5 - 29.5 (FIG 3A). The number of tests performed fell precipitously during Jun 2021 and

328 Jul 2021, as the campus population is minimal during the summer months: therefore, we are 329 reluctant to draw conclusions from or otherwise compare Summer 2021 C_T value data to the prior 330 semester, when testing volume was higher. Upon resumption of high-volume testing during the 331 later weeks of August 2021, which marked the beginning of the Autumn 2021 semester and Wave 332 4 (Week 3 of Aug 2021 \rightarrow Week 3 of Sept 2021), we noted the lowest median C_T range of all 333 waves (27.0 - 27.5) (FIG 3A). The cumulative C_T data during each wave (FIG 3C) and 334 extrapolated CoV2 genome copy concentrations (FIG 3D) are consistent with Wave 4 saliva 335 samples having the highest virus concentrations of all waves. Wave 5 was the longest wave (Week 3 of Nov 2021 \rightarrow Week 2 of Feb 2022) with daily PCR^{POS} cases reaching a maximum 336 337 of 523 on Jan 11, 2022. The C_T value range during Wave 5, which followed our community 338 deadline for vaccine requirements, was significantly higher than that of Wave 4 (FIG 3B). The last 339 wave before the COVID monitoring program ended, Wave 6 (Week 2 of Apr 2022 \rightarrow Week 1 of 340 May 2022), had lower C_T values than Wave 5 (**FIG 3B**). The lowest C_T value we ever observed 341 was on Feb 18 2021 (C_T=14.2).

342

343 IV. Each wave of CoV2 positivity corresponded to the emergence of a new CoV2 lineage
344 within our community.

345

The CoV2 lineages present in each individual PCR^{POS} sample during the same time periods as above are shown in **FIG 3B**, exceptions being samples with a C_T value of >33 as these could not be sequenced due to the viral RNA levels being too low. Among sequenced samples, the median and mean ages of infected individuals were 21 and 23, respectively, and varied minimally during the monitoring period (supplemental **FIG S3**). Males were more likely to meet sequencing criteria (i.e. a C_T ≤ 33) than females during Waves 1-3 (supplemental **FIG S4**); this was not true of later Waves, however, and female representation was higher during the entire monitoring period

353 overall (supplemental FIG S4). During the period spanning Jan 2021 to mid-Feb 2021, the 354 predominant lineage was B.1.2, which we hereafter refer to as CoV2^{US} since it was among the first detected in our region of the United States (46-48). The period of CoV2^{US} lineage 355 356 predominance corresponds to Wave 1 in our community (FIG 2, FIG 3B). Beginning mid-Feb 357 2021 and extending to mid-Mar 2021 was a period of time when an array of lineages which we 358 collectively refer to as "non-VOC" were predominant, as they were more diverse compared to 359 earlier and later testing periods and were never considered to be Variants of Concern (VOC). Although the CoV2^{US} lineage was still being detected, Wave 2 primarily comprised of non-VOCs 360 361 (FIG 3B). As the Ides of March approached in 2021, so too did two VOCs begin appearing with increasing frequency: the Alpha VOC (CoV2^{Alpha}) and Gamma VOCs (CoV2^{Gamma}). CoV2^{Alpha} and 362 363 $CoV2^{Gamma}$ were widely considered at that time to be more transmissible than previous lineages 364 (9, 67). CoV2^{Alpha} and CoV2^{Gamma} were the primary lineages detected during Wave 3 (**FIG 3B**), 365 and continued to predominate among the few positive samples collected during May 2021. The Beta VOC (CoV2^{Beta}) only appeared once in our university community (Apr 15, 2021). Beginning 366 367 Jun 2021 and continuing through Dec 2021 the new Delta VOC (CoV2^{Delta}) made up the vast majority of PCR^{POS} saliva samples (**FIG 3B**). CoV2^{Delta} is more transmissible than CoV2^{Alpha} and 368 369 CoV2^{Gamma} (68), and the period in which CoV2^{Delta} predominated coincided with COVID Wave 4 370 in our community (FIG 2). Wave 5, the penultimate and largest COVID wave, coincided with the 371 emergence and dominance of the Omicron VOC (CoV2^{Omicron}) subvariant, BA.1 (CoV2^{O-BA.1}). 372 Wave 6, final wave before our COVID monitoring program ended, was dominated by the $CoV2^{Omicron}$ subvariant BA.2 (CoV2^{O-BA.2}) (FIG 3B). When considered alongside the C_T values and 373 374 CoV2 genome copy numbers that characterized each wave (FIG 3C-D), the above data demonstrate that the shift from $CoV2^{US} \rightarrow CoV2^{Alpha}/CoV2^{Gamma} \rightarrow CoV2^{Delta}$ coincided with the 375 376 virus becoming progressively more concentrated in the saliva of asymptomatic individuals, this 377 trend ending after community vaccine requirements were established.

V. Among pre-Omicron lineages, CoV2^{Delta} elicited the highest levels of Spike-specific IgA and IgG in unvaccinated, asymptomatic individuals

381

In symptomatic CoV2 PCR^{POS} individuals, CoV2-specific lg levels in the circulation and airways 382 383 increase at variable rates depending on the isotype (22). To assess whether CoV2-specific Ig was detectable in the saliva of asymptomatic CoV2 PCR^{POS} individuals, as well as whether levels of 384 385 the same Ig varied depending on the CoV2 lineage present, we used the same samples described 386 above (i.e. those used for lineage identification) to measure saliva levels of CoV2 Spike-specific 387 IgM (IgM^{Spike}), CoV2 Spike-specific IgA (IgA^{Spike}) and CoV2 Spike-specific IgG (IgG^{Spike}) (FIG 4). 388 Individuals vaccinated against COVID were excluded from this analysis (the vaccination record 389 of each person in our university community was closely monitored during this time period), and 390 saliva samples from individuals infected with CoV2^{Anc}, CoV2^{Alpha} and CoV2^{Gamma} were collected 391 prior to COVID vaccines being widely available in our community: therefore, no vaccine-elicited 392 antibody responses would be expected in these samples. Among individuals infected with 393 CoV2^{Delta}, only unvaccinated individuals were included in the **FIG 4** analysis. To eliminate viral 394 load as a confounding variable, only PCR^{POS} saliva samples with similar C_T range were used for Ig comparisons (C_T range = 22-26). PCR^{NEG} saliva collected in early 2020 from healthy individuals 395 396 living in the US and no COVID history were used to estimate "pre-pandemic" levels of IgM^{Spike}. 397 IgA^{Spike} of IgG^{Spike} binding.

398

Saliva IgM^{Spike} (**FIG 4A**), IgA^{Spike} (**FIG 4B**) and IgG^{Spike} (**FIG 4C**) data are shown relative to which CoV2 lineage was detected in the same saliva donor (CoV2^{US}, CoV2^{Alpha}, CoV2^{Gamma} or CoV2^{Delta}) and are expressed as WHO binding antibody units, or BAUs. As shown in **FIG 4A-C**, respectively, nearly all PCR^{POS} individuals had saliva IgM^{Spike}, IgA^{Spike} and IgG^{Spike} levels that were above "prepandemic" levels, regardless of whether they were infected with CoV2^{US}, CoV2^{Alpha}, CoV2^{Gamma} or CoV2^{Delta}. There were, however, three noteworthy differences between PCR^{POS} individuals

depending on the lineage present. First, whereas individuals infected with CoV2^{US} and CoV2^{Alpha} 405 had similar IgM^{Spike} levels, those infected with CoV2^{Gamma} and CoV2^{Delta} had higher IgM^{Spike} levels 406 407 relative to those infected with CoV2^{US} (FIG 4A). Second, saliva IgA^{Spike} levels were similar between individuals infected with CoV2^{US}, CoV2^{Alpha} and CoV2^{Gamma}; CoV2^{Delta} infected 408 individuals, on the other hand, had significantly higher IgA^{Spike} levels compared to those infected 409 410 with CoV2^{US}. CoV2^{Alpha} or CoV2^{Gamma} (**FIG 4B**). Third, saliva IoG^{Spike} levels were elevated in 411 CoV2^{Alpha}-infected individuals relative to CoV2^{US}-infected individuals (**FIG 4C**); however and 412 analogous to IgA^{Spike} differences (**FIG 4B**), CoV2^{Delta}-infected individuals had significantly higher IgG^{Spike} levels compared to those infected with CoV2^{US}, CoV2^{Alpha} or CoV2^{Gamma} (**FIG 4C**). For 413 414 IgM^{Spike}, IgA^{Spike} and IgG^{Spike} measurements, the recombinant Spike antigen used for Ig detection 415 was identical to that of CoV2^{Anc}, as this enabled data transformation to WHO BAU (see *Methods*); 416 the same patterns were observed, however, when the same saliva samples were tested against 417 recombinant CoV2^{Alpha}, CoV2^{Beta}, and CoV2^{Gamma} Spike antigens (**Supplemental FIG S5**).

418

VI. Following infection of unvaccinated individuals, IgG^{Spike} and IgG^{RBD} persisted at higher levels in saliva than IgG^N

421

422 To determine the extent to which CoV2-specific IgG in saliva was sustained over time, we 423 performed the analysis shown in FIG 5 wherein saliva IgG^{Spike} levels, as well as Nucleocapsid (N)-specific IgG (IgG^N) levels, were compared across two groups of individuals: "New^{POS}" 424 individuals who, at the time of saliva collection, were positive for either CoV2^{US} or CoV2^{Alpha}; 425 426 "Prior^{POS}" individuals who were uninfected at the time of saliva collection, but had been PCR^{POS} 427 3-9 months earlier. In this instance, saliva samples from Prior^{POS} individuals were collected in May 2021. Most individuals in our Prior^{POS} cohort were infected during the Autumn 2020 semester, 428 before COVID vaccines were available; therefore, any saliva IgG^{Spike} or IgG^N present would have 429

formed after natural infection (not vaccination). As in the previous figure, individuals with a recordof COVID vaccination were excluded from this analysis.

432

433 Among New^{POS} individuals, saliva lgG^N levels were similar regardless of whether they were infected with CoV2^{US} or CoV2^{Alpha} (FIG 5A), as were saliva IgG^{Spike} levels (FIG 5B; note the data 434 435 points in the first two columns of FIG 5B are the same as those in the first two columns of FIG 436 **4C**). Relative to New^{POS} individuals, saliva IgG^N levels in Prior^{POS} individuals were higher (**FIG 5A**); however, the difference in saliva IgG^{Spike} levels between New^{POS} versus Prior^{POS} individuals 437 was more pronounced (FIG 5B). Saliva IgG^{Spike} levels were highest in Prior^{POS} individuals (FIG 438 439 **5B**) and reacted against the Spike RBD domain (**FIG 5C**). These results indicate that although IgG^N and IgG^{Spike} both persist in saliva following natural infection, IgG^{Spike} persists at higher levels 440 441 and reacts against Spike regions that are essential for ACE2 binding (i.e., the RBD).

442

VII. Individuals with breakthrough CoV^{Delta} infections had comparable saliva IgG^{Spike} levels
 to those of uninfected, vaccinated individuals.

445

446 During the period of Dec 2020 – Mar 2021, COVID vaccination was prioritized and available to 447 the elderly and other individuals at increased risk of severe disease (e.g. healthcare workers, first 448 responders). In Ohio, beginning on Mar 22 2021, individuals who were 16 years or older could 449 receive a COVID vaccine, including all college students (69). Despite the widespread availability of vaccines by our Autumn 2021 semester, CoV2^{Delta} lineage infections occurred among 450 451 unvaccinated (Vax^{NEG}) individuals and vaccinated (Vax^{POS}) individuals. The term "breakthrough 452 infection" is older than COVID (70) but is now commonly applied to individuals who are PCRPOS despite their being Vax^{POS}. Since BNT162b2, mRNA-1273 and Ad26.COV2.S were each 453 454 designed to elicit an Ig response against CoV2 Spike (since it is essential for CoV2 infection of ACE2-expressing cells), we assessed whether breakthrough infections with CoV2^{Delta} were 455

456 associated with lower levels of Spike-specific lg in saliva compared to PCR (neg) vaccinates. Shown in **FIG 6** are saliva levels of IgM^{Spike}, IgA^{Spike} and IgG^{Spike} in three groups of individuals: 457 VAX^{NEG}PCR^{POS} individuals infected with CoV2^{Delta}, VAX^{POS}PCR^{POS} individuals infected with 458 CoV2^{Delta}, and VAX^{POS}PCR^{NEG} individuals. Saliva from VAX^{NEG}PCR^{POS} and VAX^{POS}PCR^{POS} 459 460 individuals was collected during Wave 4 (FIG 2), when community viral burdens were their highest 461 (**FIG 3D**): saliva from VAX^{POS}PCR^{NEG} individuals was collected shortly after Wave 4 had passed. These results demonstrate that VAX^{POS}PCR^{POS} and VAX^{POS}PCR^{NEG} groups each had significantly 462 higher saliva lgG^{Spike} levels than VAX^{NEG}PCR^{POS} individuals (**FIG 6C**). Furthermore, the saliva 463 IgG^{Spike} levels of VAX^{POS}PCR^{POS} and VAX^{POS}PCR^{NEG} groups did not significantly differ from one 464 another (**FIG 6C**). Notably, although saliva IgM^{Spike} levels were indistinguishable across groups 465 466 (FIG 6A), VAX^{NEG}PCR^{POS} individuals were distinguished by the highest levels of saliva IgA^{Spike} (FIG 6B). Similar trends were observed using recombinant CoV2^{Alpha}, CoV2^{Beta}, CoV2^{Gamma} and 467 468 CoV2^{Delta} Spike as capture antigens (Supplemental FIG S6). We conclude from this that COVID vaccination increased saliva IgG^{Spike} levels in our university community as intended, the saliva 469 470 IgG^{Spike} levels in all vaccinees being comparable (regardless of whether they had a breakthrough CoV^{Delta} infection) and significantly higher than the saliva IgG^{Spike} levels of unvaccinated, infected 471 472 individuals.

473

VIII. Despite comparable Spike-specific Ig levels, CoV2^{Delta}-infected vaccinee saliva was
 less capable of Spike:ACE2 inhibition, relative to uninfected vaccinees.

476

Since the presence of CoV2-specific Ig does not equate to its having neutralization capacity (71), we next compared the ability of Vax^{NEG}PCR^{POS}, Vax^{POS}PCR^{POS} and Vax^{POS}PCR^{NEG} saliva samples to inhibit Spike:ACE2 interactions. We quantified inhibitory activity using an ACE2 displacement assay (**FIG 7A**), wherein plate-bound Spike was incubated with the same saliva samples above (i.e., those of **FIG 6**), followed by washing and addition of a luminescent probe-

482 conjugated, recombinant form of human ACE2. The extent to which luminescence declined 483 relative to non-saliva treated wells was used to derive a percent inhibition value for each individual 484 sample (see Methods for additional details). The results of this analysis are shown in FIG 7B and 485 demonstrate that there were differences between cohorts, the inhibitory activity of VAX^{POS}PCR^{NEG} saliva being significantly higher than that of Vax^{NEG}PCR^{POS} saliva (**FIG 7B**). The inhibitory activity 486 of Vax^{POS}PCR^{POS} saliva (median=12) was 50% higher than that of Vax^{NEG}PCR^{POS} saliva 487 (median=8), but 25% lower than that of Vax^{POS}PCR^{NEG} saliva (median=16); as a whole, however, 488 the inhibitory activity of Vax^{POS}PCR^{POS} saliva did not significantly differ from that of Vax^{NEG}PCR^{POS} 489 saliva, nor did it significantly differ from Vax^{POS}PCR^{NEG} saliva (FIG 7B). Within the Vax^{NEG}PCR^{POS} 490 491 cohort, there were no significant correlations between these samples' inhibitory activity and their 492 IaM^{Spike} (FIG 7C), IaA^{Spike} (FIG 7D) or IaG^{Spike} concentrations (FIG 7E). This was also true of the Vax^{POS}PCR^{POS} cohort, as no significant correlations were observed between these samples' 493 inhibitory activity and their IgM^{Spike} (FIG 7F), IgA^{Spike} (FIG 7G) or IgG^{Spike} concentrations (FIG 7H). 494 495 Within the Vax^{POS}PCR^{NEG} cohort, there were significant correlations between samples' inhibitory 496 activity and their IgA^{Spike} concentration (**FIG 7J**), as well as their IgG^{Spike} concentration (**FIG 7K**), 497 but not their IgM^{Spike} concentration (FIG 7I). When considered alongside the data shown in FIG 498 6, we conclude COVID vaccination led to increases in saliva IgG^{Spike} concentrations, the levels being similar between vaccinees who had a breakthrough CoV2^{Delta} infection (Vax^{POS}PCR^{POS}) and 499 vaccinees who did not (Vax^{POS}PCR^{NEG}), but that during Wave 4 the antibodies in Vax^{POS}PCR^{POS} 500 501 saliva were limited in their ability to inhibit Spike, the inhibition values being intermediate between Vax^{POS}PCR^{NEG} saliva (which had the highest inhibition values) and Vax^{NEG}PCR^{POS} controls (which 502 503 had the lowest inhibition values).

504 **DISCUSSION**

505

506 The spread of CoV2 to the US marked the beginning of an extraordinary period wherein a novel 507 respiratory virus transmitted and evolved in a population with no prior immunity, our primary 508 defenses being behavioral changes (e.g., masking and physical distancing) until the advent of 509 effective vaccines. The first COVID case in the US occurred in January 2020 (72). It was soon 510 discovered that CoV2 caused both symptomatic and asymptomatic infections (the latter being 511 more common in young adults), that asymptomatic individuals could transmit CoV2 (73, 74), and 512 that isolation of symptomatic individuals alone would not sufficiently "flatten the curve" of COVID 513 incidence (37, 75). By April 2020, most US universities shut down on-campus activities so as to 514 limit CoV2 transmission among their students, staff, and faculty. Many universities established 515 COVID monitoring programs prior to campus reopening as a means of identifying symptomatic 516 and asymptomatic individuals. These monitoring programs varied in their testing modalities (PCR-517 or antigen-based), cadence (weekly versus biweekly testing) and sample pooling practices 518 (pooled versus individual testing); all monitoring programs, however, had the same goal in mind: 519 enabling safe resumption of on-campus classes and activities. Now that mass COVID testing 520 programs have ended in US, enabling time for processing and reflection, we are sharing the 521 results of our monitoring program which we believe are most relevant to the ongoing issues of 522 community spread, the longevity of mucosal Ig following natural infection, breakthrough infections, 523 and the utility of saliva for assessing Ig responses to newer Omicron subvariants and booster 524 vaccines.

525

526 That the COVID waves in our campus community mirrored those which occurred in surrounding 527 counties, instead of preceding the surrounding county waves, touches on an important question 528 at the time regarding campus reopening: what if any contribution would the influx of students have 529 on COVID incidence in surrounding communities. In January 2021, student returns to university

530 campuses were a contentious subject in the US due to the potential risk of contracting the virus 531 and subsequent transmission to surrounding communities. COVID vaccines were not yet widely 532 available to young adults, and-fairly or unfairly-university students were perceived as being 533 more cavalier in their adherence to masking protocols and social distancing. Whether or not the 534 reopening of a given college or university contributed to higher off-campus COVID transmission 535 will depend on several variables (e.g. whether a school was in a state that mandated mask-536 wearing) (76), but in our case the COVID wave that occurred in our university in January 2021 537 (Wave 1) peaked during the tail end of one which had been ongoing in surrounding counties 538 (compare FIG 2 to supplemental FIG S2). This was also true in Aug 2022, when our campus 539 reopened after summer break and experienced Wave 4, which followed the Delta wave that had 540 already begun in surrounding counties. The timing of Wave 1 and Wave 4 in relation to those in 541 surrounding counties is inconsistent with the argument that our university reopening contributed 542 to COVID incidence in the surrounding communities. Studies at other large universities with 543 COVID policies and monitoring programs similar to our own support this conclusion (77-79).

544

545 Early in the COVID pandemic, it was unknown whether natural infection would give rise to Ig 546 responses that were durable and protective, as those against common seasonal coronaviruses 547 are short-lived (only 6 months in some cases) (80), or worse still whether the lg response would 548 actually enhance infection or disease (81-84). Regarding the durability and protective capacity of 549 the antibody response to natural CoV2 infection, current knowledge on this subject was recently 550 reviewed (71). In our study, at the time of initial PCR positivity we could already detect elevations 551 in CoV2-specific Ig (IgM, IgA, and to a lesser extent IgG) in the saliva of asymptomatic individuals, the degree to which varied by lineage, CoV2^{Delta} being the most immunogenic of the lineages we 552 553 assessed. Saliva levels of CoV2-specific IgG were substantially higher in Prior^{POS} individuals 554 compared to New^{POS} individuals, were directed against Spike, Spike RBD and (to a lesser extent)

555 the N protein. Potential reasons why Spike-specific IgG (IgG^{Spike}) levels were higher than those 556 of N-specific IgG (IgG^N) include Spike being more antigenic, or alternatively it may reflect an inherent inability of IgG^N to persist in saliva relative to IgG^{Spike}, as is the case in plasma (85). With 557 558 regards to antibody dependent enhancement (ADE) of virus infection or subsequent disease, this 559 has primarily been studied in the context of flaviviruses (86) and is the phenomenon wherein non-560 neutralizing antibodies amplify viral entry (instead of blocking it). ADE occurs in cell culture and 561 animal infection models of SARS-CoV-1 (87, 88) and MERS-CoV (89), as well as feline infectious 562 peritonitis coronavirus (FIPV) (90, 91). B cells from convalescent COVID patients can produce 563 monoclonal antibodies that enhance the ACE2-binding capacity of Spike and CoV2 infectivity in 564 cell culture (92, 93); however, these same monoclonal antibodies did not enhance CoV2 infection 565 in mouse or macaque models (92), nor has evidence of vaccine-enhanced disease (VED) been 566 observed in the hamster, ferret or macaque COVID models (94, 95). The circumstances and 567 extent to which ADE occurring following CoV2 infection nevertheless remains an active area of 568 research (96-98).

569 When COVID vaccine doses were in short supply (early 2021), university students were generally 570 not considered a vaccine priority by national public health agencies. By the time COVID vaccines 571 were widely available, non-trivial levels of vaccine hesitancy had arisen among university students 572 in many countries for many reasons (99). Vaccine hesitancy was reinforced by the occurrence of 573 breakthrough infections with CoV2^{Delta} (100, 101), the first lineage to emerge after vaccines had 574 become more widely available in Summer 2021. If vaccines were effective, conventional logic at the time being, how then could a vaccinated individual still become PCR^{POS}? Our current 575 576 understanding is that a combination of three factors affects susceptibility to breakthrough 577 infections: (1) antibody levels at the time of virus exposure, (2) the neutralizing capacity of these 578 antibodies, and (3) the amount of virus to which a vaccinee is exposed. Our data demonstrate that saliva IqG^{Spike} levels were comparable between CoV^{Delta}-infected vaccinees (Vax^{POS}PCR^{POS}) 579

and uninfected vaccinees (Vax^{POS}PCR^{NEG}), but that the collective inhibitory capacity of this 580 581 IgG^{Spike} and other saliva antibodies differed between groups, with Vax^{POS}PCR^{POS} saliva being less 582 inhibitory than Vax^{POS}PCR^{NEG} saliva (**FIG 7B**). If the saliva lq response is representative of that 583 which occurs in other parts of the upper airway, then the combination of weak neutralization 584 capacity and higher viral loads, which were typical of the Delta wave (Wave 4 of FIG 3D), created conditions that were conducive to CoV2^{Delta} breakthrough infections. Our observation that 585 586 CoV2^{Delta} was more concentrated in saliva of asymptomatic individuals is consistent with work 587 showing CoV2^{Delta}-infected individuals were more likely to transmit virus before developing 588 symptoms, compared to individuals infected with pre-Delta lineages (102).

589

590 The largest COVID wave our university community experienced was caused by the Omicron 591 lineage. The Omicron lineage spread rapidly after its first detection in southern Africa in November 592 2021 (11, 103): the >30 amino acid substitutions in Spike enabled Omicron to bind ACE2 with 593 higher affinity, as well as escape the anti-Spike antibody response elicited by either natural 594 infection or vaccination with pre-Omicron lineages or vaccines (104-106). The immunoevasive 595 properties of Omicron are consistent with its causing a COVID wave in our community after 596 vaccine mandates had been established. The rapidity with which Omicron took over was observed 597 in other university settings which, like ours, were highly vaccinated at the time (107). Compared 598 to infections caused by the Delta lineage, those by Omicron tend to cause less severe disease 599 (108), which may be due in whole or part to its being enriched in upper airways (including the oral 600 cavity) as opposed to the lower airways (39-43). Omicron variants BA.1 and BA.2 were the last 601 lineages detected in our university community before our testing program ended in May 2022. 602 Since then CoV2 has continued to evolve, there now being additional Omicron variants (BA.4, 603 BA.5, BA.2.12.1, BA.2.75, XBB) and "Scrabble" subvariants (BQ.1 and BQ1.1) with Spike protein 604 sequences that further desensitize the virus to *in vitro* neutralization by many (but not all) 605 monoclonal therapies (109-112), as well as convalescent plasma (113). Since Omicron has a

higher tropism for the nasopharyngeal and oral cavities than that of pre-Omicron lineages (39-43), saliva antibodies may be more important inhibitors of Omicron transmission than plasma or lower airway antibodies, and saliva—the collection of which is far easier than blood—may be more suitable for rapid determination of whether someone has neutralizing capacity against future CoV2 variants that have yet to emerge.

611

612 The limitations of our study are as follows: (1) Since participants in our monitoring program 613 provided saliva on a weekly basis, we cannot know the exact date on which someone was 614 infected, rather only that they were infected 0-7 days prior to their scheduled test; (2) By only 615 measuring CoV2-specific Ig in individuals whose C_T values fell within a narrow range (thus 616 normalizing for viral load), we cannot make any statements regarding the relationship between 617 lower or higher C_T values and CoV2-specific Ig levels; (3) Although we can correlate saliva 618 samples' Spike inhibition capacity with their corresponding IgM^{Spike}, IgA^{Spike} and IgG^{Spike} levels, we 619 cannot definitively state which of these isotypes most contributed to inhibition; (4) Finally, we did not measure CoV2-specific Ig levels in individuals infected with CoV2^{O-BA.1} or CoV2^{O-BA.2}, a reason 620 621 being at that stage in the pandemic (i.e. Waves 5-6 in our community) vaccine mandates were in 622 place, and boosters were becoming available, making it difficult if not impossible to discern what 623 levels of IgM^{Spike}, IgA^{Spike} and IgG^{Spike} were due to vaccination versus boosters versus Omicron 624 infection.

625 ACKNOWLEDGEMENTS

626 We would like to acknowledge the hundreds of Ohio State staff and student employees who 627 collected, transported and processed saliva during the period that our campus testing program 628 was active. We would also like to acknowledge the research compliance expertise of Tish 629 Denlinger (Office of Responsible Research Practices) and Angela Emerson (Office of Research), 630 the technical expertise of Dr. Arpita Agrawal, Brian Gribble, and Trina Wemlinger (Center for 631 Clinical and Translational Science), the general lab assistance of Sam Hagenbaugh and Elizabeth 632 Griffin (TOPS Program), and documentation assistance of Marie Klever (Infectious Disease 633 Institute). This work was supported by the Analytical and Development Laboratory of the Clinical 634 Research Center/Center for Clinical Research Management of Wexner Medical Center, the OSU 635 College of Medicine (Microbial Infection & Immunity Department), OSU College of Public Health 636 (Epidemiology Division), and the OSU Infectious Disease Institute.

637 **REFERENCES**

- G. T. Keusch *et al.*, Pandemic origins and a One Health approach to preparedness and
 prevention: Solutions based on SARS-CoV-2 and other RNA viruses. *Proc Natl Acad Sci U*S A **119**, e2202871119 (2022).
- 641 2. <u>https://covid19.who.int</u>.
- 642
 3.
 S. E. Galloway *et al.*, Emergence of SARS-CoV-2 B.1.1.7 Lineage United States, December

 643
 29, 2020-January 12, 2021. MMWR Morb Mortal Wkly Rep **70**, 95-99 (2021).
- H. Tegally *et al.*, Detection of a SARS-CoV-2 variant of concern in South Africa. *Nature* 592,
 438-443 (2021).
- 6465.J. P. Evans, S. L. Liu, Role of host factors in SARS-CoV-2 entry. J Biol Chem 297, 100847647(2021).
- 648 6. D. Zhou *et al.*, Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-649 induced sera. *Cell* **184**, 2348-2361 e2346 (2021).
- 650 7. E. Volz *et al.*, Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. *Nature*651 593, 266-269 (2021).
- 8. N. G. Davies *et al.*, Increased mortality in community-tested cases of SARS-CoV-2 lineage
 B.1.1.7. *Nature* 593, 270-274 (2021).
- 9. N. R. Faria *et al.*, Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus,
 Brazil. *Science* 372, 815-821 (2021).
- P. Mlcochova *et al.*, SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. *Nature* 599, 114-119 (2021).
- 65811.R. Viana *et al.*, Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern659Africa. Nature **603**, 679-686 (2022).
- 660 12. J. Scholey *et al.*, Life expectancy changes since COVID-19. *Nat Hum Behav*, (2022).
- 13. J. Q. Xu, S. L. Murphy, K. D. Kochanek, E. Arias, Mortality in the United States, 2021. NCHS
 Data Brief, no 456. Hyattsville, MD: National Center for Health Statistics., (2022).
- 4. J. Zhao *et al.*, Rapid generation of a mouse model for Middle East respiratory syndrome. *Proc Natl Acad Sci U S A* **111**, 4970-4975 (2014).
- 66515.Y. Yao *et al.*, An animal model of MERS produced by infection of rhesus macaques with666MERS coronavirus. J Infect Dis **209**, 236-242 (2014).
- 16. T. H. Jang *et al.*, The structure of a novel antibody against the spike protein inhibits Middle
 East respiratory syndrome coronavirus infections. *Sci Rep* **12**, 1260 (2022).
- L. Du *et al.*, A conformation-dependent neutralizing monoclonal antibody specifically
 targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike
 protein. *J Virol* 88, 7045-7053 (2014).
- 672 18. C. Ma *et al.*, Intranasal vaccination with recombinant receptor-binding domain of MERS673 CoV spike protein induces much stronger local mucosal immune responses than
 674 subcutaneous immunization: Implication for designing novel mucosal MERS vaccines.
 675 Vaccine **32**, 2100-2108 (2014).
- F. Song *et al.*, Middle East respiratory syndrome coronavirus spike protein delivered by
 modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. *J Virol* 87,
 11950-11954 (2013).

679	20.	L. Du et al., Identification of a receptor-binding domain in the S protein of the novel
680		human coronavirus Middle East respiratory syndrome coronavirus as an essential target
681		for vaccine development. <i>J Virol</i> 87 , 9939-9942 (2013).

- H. Mou *et al.*, The receptor binding domain of the new Middle East respiratory syndrome
 coronavirus maps to a 231-residue region in the spike protein that efficiently elicits
 neutralizing antibodies. *J Virol* 87, 9379-9383 (2013).
- 685 22. D. Sterlin *et al.*, IgA dominates the early neutralizing antibody response to SARS-CoV-2.
 686 Sci Transl Med 13, (2021).
- 687 23. D. Kline *et al.*, Estimating seroprevalence of SARS-CoV-2 in Ohio: A Bayesian multilevel
 688 poststratification approach with multiple diagnostic tests. *Proc Natl Acad Sci U S A* **118**,
 689 (2021).
- 69024.D. F. Robbiani *et al.*, Convergent antibody responses to SARS-CoV-2 in convalescent691individuals. *Nature* 584, 437-442 (2020).
- 69225.E. M. Bloch *et al.*, Deployment of convalescent plasma for the prevention and treatment693of COVID-19. J Clin Invest **130**, 2757-2765 (2020).
- 69426.L. Estcourt, J. Callum, Convalescent Plasma for Covid-19 Making Sense of the695Inconsistencies. N Engl J Med **386**, 1753-1754 (2022).
- 69627.https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-697against-covid-19-issuing-emergency-use-authorization-first-covid-19.
- 69828.https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-699fight-against-covid-19-issuing-emergency-use-authorization-second-covid.
- 70029.https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-701authorization-third-covid-19-vaccine.
- 702
 30.
 D. H. Barouch, Covid-19 Vaccines Immunity, Variants, Boosters. N Engl J Med 387, 1011

 703
 1020 (2022).
- A. G. Johnson *et al.*, COVID-19 Incidence and Death Rates Among Unvaccinated and Fully
 Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron
 Variant Emergence 25 U.S. Jurisdictions, April 4-December 25, 2021. *MMWR Morb Mortal Wkly Rep* **71**, 132-138 (2022).
- 708
 32.
 L. R. Baden *et al.*, Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med*

 709
 384, 403-416 (2021).
- 710
 33.
 F. P. Polack *et al.*, Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J*

 711
 Med 383, 2603-2615 (2020).
- 712 34. D. Bojadzic *et al.*, Small-Molecule Inhibitors of the Coronavirus Spike: ACE2 Protein713 Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2. *ACS Infect*714 *Dis* 7, 1519-1534 (2021).
- Y. Huang, C. Yang, X. F. Xu, W. Xu, S. W. Liu, Structural and functional properties of SARSCoV-2 spike protein: potential antivirus drug development for COVID-19. *Acta Pharmacol Sin* 41, 1141-1149 (2020).
- W. S. Hart, P. K. Maini, R. N. Thompson, High infectiousness immediately before COVID19 symptom onset highlights the importance of continued contact tracing. *Elife* 10,
 (2021).
- 72137.M. A. Johansson *et al.*, SARS-CoV-2 Transmission From People Without COVID-19722Symptoms. JAMA Netw Open 4, e2035057 (2021).

723	38.	N. Huang et al., SARS-CoV-2 infection of the oral cavity and saliva. Nat Med 27, 892-903
724		(2021).
725	39.	M. Migueres et al., Omicron Wave SARS-CoV-2 Diagnosis: Evaluation of Saliva, Anterior
726		Nasal, and Nasopharyngeal Swab Samples. <i>Microbiol Spectr</i> , e0252122 (2022).
727	40.	G. Marais <i>et al.</i> , Improved oral detection is a characteristic of Omicron infection and has
728		implications for clinical sampling and tissue tropism. J Clin Virol 152 , 105170 (2022).
729	41.	R. Suzuki <i>et al.</i> , Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron
730		variant. <i>Nature</i> 603 , 700-705 (2022).
731	42.	K. P. Y. Hui <i>et al.</i> , Replication of SARS-CoV-2 Omicron BA.2 variant in ex vivo cultures of
732		the human upper and lower respiratory tract. <i>EBioMedicine</i> 83 , 104232 (2022).
733	43.	B. Meng <i>et al.</i> , Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and
734		fusogenicity. <i>Nature</i> 603 , 706-714 (2022).
735	44.	https://www.fda.gov/media/141192/download.
736	45.	C. B. F. Vogels <i>et al.</i> , SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-
737		2 testing capacity. <i>Med (N Y)</i> 2 , 263-280 e266 (2021).
738	46.	V. L. Hale <i>et al.</i> , SARS-CoV-2 infection in free-ranging white-tailed deer. <i>Nature</i> 602 , 481-
739		486 (2022).
740	47.	A. Rambaut <i>et al.</i> , A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist
741		genomic epidemiology. Nat Microbiol 5, 1403-1407 (2020).
742	48.	E. B. Hodcroft et al., Emergence in late 2020 of multiple lineages of SARS-CoV-2 Spike
743		protein variants affecting amino acid position 677. <i>medRxiv</i> , (2021).
744	49.	E. I. Patterson et al., Methods of Inactivation of SARS-CoV-2 for Downstream Biological
745		Assays. J Infect Dis 222 , 1462-1467 (2020).
746	50.	https://www.dispatch.com/story/news/2020/03/09/3-ohioans-test-positive-
747		<u>for/1553817007/</u> .
748	51.	https://www.thelantern.com/2020/03/ohio-state-suspends-classes-until-march-30-due-
749		to-coronavirus-outbreak/.
750	52.	https://www.thelantern.com/2020/07/ohio-state-announces-proactive-covid-19-
751		testing-measures-no-specific-guidance-on-when-to-close-campus/.
752	53.	https://news.osu.edu/ohio-state-announces-vaccination-requirement/.
753	54.	Data were obtained from <u>https://coronavirus.ohio.gov/dashboards/overview</u> accessed
754		11.14.22.
755	55.	Ohio Department of Health COVID-19 Dashboard.
756		https://coronavirus.ohio.gov/dashboards.
757	56.	https://www.who.int/news/item/15-01-2021-statement-on-the-sixth-meeting-of-the-
758		international-health-regulations-(2005)-emergency-committee-regarding-the-
759		<u>coronavirus-disease-(covid-19)-pandemic</u> .
760	57.	https://www.daytondailynews.com/local/delta-variant-in-ohio-what-you-should-
761		know/WQ3EI57ZPNA67OC346RKSDCKAU/
762	58.	https://governor.ohio.gov/media/news-and-media/COVID-19-Update-Vaccinations-
763	_	Increasing-Delta-Variant-Local-Efforts-Encouraged-08062021.
764	59.	https://www.10tv.com/article/news/health/coronavirus/covid-variant-dashboard/530-
765	_	<u>0a10581c-cf0b-4255-b2f0-46984b0cbd30</u> .
766	60.	https://odh.ohio.gov/media-center/odh-news-releases/odh-news-release-12-11-21.

767	61.	https://www.thelantern.com/2021/12/first-cases-of-omicron-covid-19-variant-
768		detected-in-ohio/.
769	62.	Y. Woodbridge, S. Amit, A. Huppert, N. M. Kopelman, Viral load dynamics of SARS-CoV-2
770		Delta and Omicron variants following multiple vaccine doses and previous infection. Nat
771		<i>Commun</i> 13 , 6706 (2022).
772	63.	M. Trunfio et al., Determinants of SARS-CoV-2 Contagiousness in Household Contacts of
773		Symptomatic Adult Index Cases. Front Microbiol 13, 829393 (2022).
774	64.	M. Levine-Tiefenbrun et al., Viral loads of Delta-variant SARS-CoV-2 breakthrough
775		infections after vaccination and booster with BNT162b2. <i>Nat Med</i> 27 , 2108-2110 (2021).
776	65.	S. Al Bayat <i>et al.</i> , Can the cycle threshold (Ct) value of RT-PCR test for SARS CoV2 predict
777		infectivity among close contacts? J Infect Public Health 14, 1201-1205 (2021).
778	66.	H. Kawasuji et al., Transmissibility of COVID-19 depends on the viral load around onset in
779		adult and symptomatic patients. <i>PLoS One</i> 15 , e0243597 (2020).
780	67.	N. G. Davies et al., Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in
781		England. <i>Science</i> 372 , (2021).
782	68.	W. S. Hart et al., Generation time of the alpha and delta SARS-CoV-2 variants: an
783		epidemiological analysis. Lancet Infect Dis 22, 603-610 (2022).
784	69.	https://www.thelantern.com/2021/04/dewine-all-ohio-college-students-will-have-
785		access-to-single-dose-covid-vaccine/.
786	70.	J. L. Mahoney, Malaria 'breakthroughs' and resistance to chloroquine in Africa. Case
787		reports. <i>S Afr Med J</i> 60 , 786-788 (1981).
788	71.	A. Sette, S. Crotty, Immunological memory to SARS-CoV-2 infection and COVID-19
789		vaccines. <i>Immunol Rev</i> 310 , 27-46 (2022).
790	72.	M. L. Holshue et al., First Case of 2019 Novel Coronavirus in the United States. N Engl J
791		Med 382 , 929-936 (2020).
792	73.	Y. Bai et al., Presumed Asymptomatic Carrier Transmission of COVID-19. JAMA 323, 1406-
793		1407 (2020).
794	74.	C. Rothe et al., Transmission of 2019-nCoV Infection from an Asymptomatic Contact in
795		Germany. <i>N Engl J Med</i> 382 , 970-971 (2020).
796	75.	B. Nussbaumer-Streit et al., Quarantine alone or in combination with other public health
797		measures to control COVID-19: a rapid review. Cochrane Database Syst Rev 9, CD013574
798		(2020).
799	76.	C. N. Chang, H. Y. Chien, L. Malagon-Palacios, College reopening and community spread
800		of COVID-19 in the United States. <i>Public Health</i> 204 , 70-75 (2022).
801	77.	C. R. K. Arnold et al., A longitudinal study of the impact of university student return to
802		campus on the SARS-CoV-2 seroprevalence among the community members. Sci Rep 12,
803		8586 (2022).
804	78.	N. Bharti et al., Large university with high COVID-19 incidence is not associated with
805		excess cases in non-student population. Sci Rep 12, 3313 (2022).
806	79.	B. H. Pollock et al., Safe reopening of college campuses during COVID-19: The University
807		of California experience in Fall 2020. PLoS One 16, e0258738 (2021).
808	80.	A. W. D. Edridge et al., Seasonal coronavirus protective immunity is short-lasting. Nat Med
809		26 , 1691-1693 (2020).

- 81. W. S. Lee, A. K. Wheatley, S. J. Kent, B. J. DeKosky, Antibody-dependent enhancement and
 811 SARS-CoV-2 vaccines and therapies. *Nat Microbiol* 5, 1185-1191 (2020).
- 812 82. A. M. Arvin *et al.*, A perspective on potential antibody-dependent enhancement of SARS-813 CoV-2. *Nature* **584**, 353-363 (2020).
- 814 83. B. S. Graham, Rapid COVID-19 vaccine development. *Science* **368**, 945-946 (2020).
- 815 84. A. Iwasaki, Y. Yang, The potential danger of suboptimal antibody responses in COVID-19.
 816 Nat Rev Immunol 20, 339-341 (2020).
- 817 85. J. Van Elslande *et al.*, Lower persistence of anti-nucleocapsid compared to anti-spike
 818 antibodies up to one year after SARS-CoV-2 infection. *Diagn Microbiol Infect Dis* 103,
 819 115659 (2022).
- 820 86. K. A. Dowd, T. C. Pierson, Antibody-mediated neutralization of flaviviruses: a reductionist
 821 view. *Virology* 411, 306-315 (2011).
- 822 87. S. F. Wang *et al.*, Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. *Biochem Biophys Res Commun* **451**, 208-214 (2014).
- 824 88. Y. W. Kam *et al.*, Antibodies against trimeric S glycoprotein protect hamsters against SARS825 CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells
 826 in vitro. *Vaccine* 25, 729-740 (2007).
- 827 89. Y. Wan *et al.*, Molecular Mechanism for Antibody-Dependent Enhancement of 828 Coronavirus Entry. *J Virol* **94**, (2020).
- 829 90. T. Takano, C. Kawakami, S. Yamada, R. Satoh, T. Hohdatsu, Antibody-dependent
 830 enhancement occurs upon re-infection with the identical serotype virus in feline
 831 infectious peritonitis virus infection. *J Vet Med Sci* **70**, 1315-1321 (2008).
- 832 91. T. Hohdatsu *et al.*, Antibody-dependent enhancement of feline infectious peritonitis virus
 833 infection in feline alveolar macrophages and human monocyte cell line U937 by serum of
 834 cats experimentally or naturally infected with feline coronavirus. *J Vet Med Sci* 60, 49-55
 835 (1998).
- 83692.D. Li *et al.*, In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and837neutralizing antibodies. *Cell* **184**, 4203-4219 e4232 (2021).
- 83893.Y. Liu *et al.*, An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by839antibodies. *Cell* **184**, 3452-3466 e3418 (2021).
- 840 94. K. R. Bewley *et al.*, Immunological and pathological outcomes of SARS-CoV-2 challenge
 841 following formalin-inactivated vaccine in ferrets and rhesus macaques. *Sci Adv* 7,
 842 eabg7996 (2021).
- 843 95. C. Li *et al.*, Absence of Vaccine-enhanced Disease With Unexpected Positive Protection
 844 Against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by Inactivated
 845 Vaccine Given Within 3 Days of Virus Challenge in Syrian Hamster Model. *Clin Infect Dis*846 **73**, e719-e734 (2021).
- 847 96. H. S. Ismanto *et al.*, Landscape of infection enhancing antibodies in COVID-19 and healthy
 848 donors. *Comput Struct Biotechnol J* 20, 6033-6040 (2022).
- S. Mu *et al.*, Neutralizing antibodies from the rare convalescent donors elicited antibodydependent enhancement of SARS-CoV-2 variants infection. *Front Med (Lausanne)* 9,
 952697 (2022).
- 85298.C. Gartlan *et al.*, Vaccine-Associated Enhanced Disease and Pathogenic Human853Coronaviruses. Front Immunol 13, 882972 (2022).

854	99.	M. Schafer et al., Determinants of university students' COVID-19 vaccination intentions
855		and behavior. <i>Sci Rep</i> 12 , 18067 (2022).

- T. Dzinamarira *et al.*, Unpacking the Implications of SARS-CoV-2 Breakthrough Infections
 on COVID-19 Vaccination Programs. *Vaccines (Basel)* 10, (2022).
- 858 101. A. Haque, A. B. Pant, Mitigating Covid-19 in the face of emerging virus variants,
 859 breakthrough infections and vaccine hesitancy. *J Autoimmun* **127**, 102792 (2022).
- M. Kang *et al.*, Transmission dynamics and epidemiological characteristics of SARS-CoV-2
 Delta variant infections in Guangdong, China, May to June 2021. *Euro Surveill* 27, (2022).
- 862 103. C. Fischer *et al.*, Gradual emergence followed by exponential spread of the SARS-CoV-2
 863 Omicron variant in Africa. *Science*, eadd8737 (2022).
- 864 104. R. Nutalai *et al.*, Potent cross-reactive antibodies following Omicron breakthrough in vaccinees. *Cell* **185**, 2116-2131 e2118 (2022).
- 866 105. L. Liu *et al.*, Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2.
 867 *Nature* 602, 676-681 (2022).
- 868 106. E. Cameroni *et al.*, Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. *Nature* 602, 664-670 (2022).
- 870 107. B. A. Petros *et al.*, Early introduction and rise of the Omicron SARS-CoV-2 variant in highly
 871 vaccinated university populations. *Clin Infect Dis*, (2022).
- 872 108. N. van Doremalen *et al.*, SARS-CoV-2 Omicron BA.1 and BA.2 are attenuated in rhesus
 873 macaques as compared to Delta. *Sci Adv* 8, eade1860 (2022).
- 874 109. E. Takashita *et al.*, In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6.
 875 *N Engl J Med* 387, 2094-2097 (2022).
- 876 110. M. Cox *et al.*, SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro
 877 studies. *Nat Rev Microbiol*, 1-13 (2022).
- 878 111. Y. J. Park *et al.*, Imprinted antibody responses against SARS-CoV-2 Omicron sublineages.
 879 Science **378**, 619-627 (2022).
- M. Hoffmann *et al.*, The Omicron variant is highly resistant against antibody-mediated
 neutralization: Implications for control of the COVID-19 pandemic. *Cell* 185, 447-456 e411
 (2022).
- 883 113. P. Qu *et al.*, Evasion of neutralizing antibody responses by the SARS-CoV-2 BA.2.75
 884 variant. *Cell Host Microbe* **30**, 1518-1526 e1514 (2022).
- 885
- 886

887 FIGURE LEGENDS

888

889 FIGURE 1. Overview of our university COVID monitoring program and workflow. (A) Map 890 of Ohio with locations of the six university campuses which participated in the COVID monitoring 891 program. (B) On and prior to the day of testing, each individual assessed themselves for one or 892 more COVID symptoms (see *Methods* for complete list). If symptomatic, the individual was given 893 a clinical referral and instructed to not go to their on-campus testing facility, to prevent contagion. 894 If asymptomatic, the individual provided a saliva sample which was tested (typically within 24 895 hours of sample provision) via gRT-PCR for the presence of the CoV2 N gene. Individuals were notified as soon as possible as to whether their sample was negative (PCR^{NEG}) or positive 896 (PCR^{POS}) for the virus, a positive result being a $C_T \leq 40$. PCR^{POS} samples were subsequently 897 898 aliguoted and used for both CoV2 lineage identification and measuring the concentrations of immunoglobulin against specific CoV2 antigens (CoV2-Ig). The vast majority of PCR^{NEG} samples 899 900 were discarded; however, a minority were retained and used for CoV2-Ig measurements, PCR^{POS} 901 and PCR^{NEG} samples were otherwise treated identically.

902

903 FIGURE 2. The incidence of PCR positivity among asymptomatic members of our 904 university community. Saliva samples from asymptomatic individuals were collected on a daily 905 basis and tested by gRT-PCR for the presence of the CoV2 N gene. Shown are the number of 906 PCR^{POS} saliva samples identified each day during the period spanning Jan 2021 \rightarrow May 2022, 907 with each bar representing a single day. Above the graph is a timeline depicting when COVID 908 vaccine availability shifted in Ohio (i.e. when the national vaccination priority expanded from 909 vulnerable populations to encompass anyone >15 years of age), as well as indications of the 910 deadlines by which all university community members were required to have received their first 911 and second vaccine dose of either the BNT162b2 or mRNA-1273 vaccines. Below the graph are

912 indications of the periods we refer to as Waves 1-6, a wave being defined as when the daily 913 PCR^{POS} case count exceeded the period median (15) for \geq 3 weeks, as well Blue shading indicates 914 when the samples we used for CoV2 lg measurements were collected.

915

916 FIGURE 3. Saliva CoV2 viral loads among asymptomatic members of our university **community.** (A) Box plot representation of all the C_T values of all the PCR^{POS} saliva samples 917 during each week of the period spanning Jan 2021 \rightarrow Jun 2022. The blue line passes through 918 919 the median C_T value of each week. Below the graph are indications of the periods corresponding 920 to Waves 1-6 of the prior figure. (B) Scatter plot representation of the same C_{T} value data as in 921 (A) above, the exceptions being daily data are shown (as opposed to weekly composites) and 922 samples with a C_T >33 are omitted (these could not be sequenced due to insufficient amounts of 923 genetic material). Each dot represents an individual sample; the color of each diamond indicates the CoV2 lineage present (Green, CoV2^{US}; Pink, CoV2^{Alpha}; White, CoV2^{Beta}; Blue, CoV2^{Gamma}; 924 925 Red, CoV2^{Delta}; Gold, CoV2^{O-BA.1}; Orange, CoV2^{O-BA.2}). Gray diamonds indicate samples whose 926 lineage was not a VOC. Black squares indicate a sequence that did not align to known lineages and thus could not be assigned. Note that CoV2^{Beta} only appeared once in our university 927 928 community, on Apr 15 2021. (C) The C_T value and (D) calculated CoV2 genome copy 929 concentration in of each positive sample during Wave 1, Wave 2, Wave 3, Wave 4, Wave 5 and 930 Wave 6. The "Vax" arrow indicates when community vaccine requirements went into effect (after 931 Wave 4, before Wave 5). Asterisks indicate those inter-wave differences that were statistically 932 significant, as determined by one way ANOVA (* $p \le 0.05$, ** $p \le 0.005$, *** $p \le 0.0005$, *** 933 0.00005).

934

FIGURE 4. Spike-specific Ig levels in the saliva of newly positive, asymptomatic individuals
at the time of PCR testing. Saliva samples from individuals who were newly positive (New^{POS},

PCR positive for the first time ever) for either the CoV2^{US}. CoV2^{Alpha}. CoV2^{Gamma} or CoV2^{Delta} 937 lineage were used to measure the concentrations of (A) IgM^{Spike}, (B) IgA^{Spike} and (C) IgG^{Spike}. The 938 939 CoV2^{Anc} Spike was used as the capture antigen in each case, and concentrations are expressed as World Health Organization (WHO) binding antibody units (BAU) per mL. PCR^{NEG} saliva 940 941 collected in early 2020, from healthy individuals living in the US with no COVID history, was tested in the same manner used to estimate "pre-pandemic" levels of IgM^{Spike}. IgA^{Spike} and IgG^{Spike} 942 943 binding, which are represented by the dashed lines on each graph. ^X, values that were considered 944 outliers but are nevertheless shown for completeness and are included in all statistical group 945 comparisons. * $p \le 0.05$. as determined by unpaired Wilcoxon tests with Benjamini-Hochberg 946 adjustment.

947

948FIGURE 5. Nucleocapsid- and Spike-specific IgG levels in saliva of newly positive,949asymptomatic individuals versus prior positive, asymptomatic individuals. Saliva from950New^{POS} individuals infected with either $CoV2^{US}$ or $CoV2^{Alpha}$, as well as PCR^{NEG} saliva from951individuals who had been infected 3-9 months prior (Prior^{POS}) with either $CoV2^{US}$, $CoV2^{Alpha}$ or a952non-VOC, were used to measure the concentrations of (A) Nucleocapsid-specific IgG, (B) Spike-953specific IgG, and (C) Spike RBD-specific IgG. * $p \le 0.05$, as determined by unpaired Wilcoxon test954with Benjamini-Hochberg adjustment.

955

956 FIGURE 6. Spike-specific Ig levels in saliva of CoV2^{Deita}-infected unvaccinated individuals, 957 CoV2^{Deita}-infected vaccinees, and uninfected vaccinees. During and shortly after COVID 958 Wave 4 (i.e. that which was caused by CoV2^{Deita}), saliva from three groups of individuals were 959 collected and used for Ig measurements: those who had not been fully vaccinated and were 960 positive for the CoV2^{Deita} lineage (Vax^{NEG}PCR^{POS}), those who had been fully vaccinated and were 961 positive for the CoV2^{Deita} lineage (Vax^{POS}PCR^{POS}), and those who had been fully vaccinated and

were negative for any CoV2 lineage (Vax^{POS}PCR^{NEG}). Shown are the (**A**) IgM^{Spike}, (**B**) IgA^{Spike} and (**C**) IgG^{Spike} levels in each individual sample per group. ^X, values that were considered outliers but are nevertheless shown for completeness and are included in all statistical group comparisons. * $p \le 0.05$, as determined by unpaired Wilcoxon tests with Benjamini-Hochberg adjustment.

966

FIGURE 7. Inhibition of Spike function by saliva of CoV2^{Delta}-infected unvaccinated 967 968 individuals, CoV2^{Delta}-infected vaccinees, and uninfected vaccinees (A) Depiction of the 969 probe-conjugated ACE2 displacement assay used to measure saliva samples' ability to inhibit 970 CoV2 Spike binding to its human receptor, ACE2. The samples in this case were from 971 VAX^{NEG}PCR^{POS}, VAX^{POS}PCR^{POS} and VAX^{POS}PCR^{NEG} individuals (the same samples used for 972 IgM^{Spike}, IgA^{Spike} and IgG^{Spike} measurements in **FIG 6** above). (**B**) The percent inhibition value of each individual sample in each group. Within the (**C-E**) VAX^{NEG}PCR^{POS} group, (**F-H**) 973 974 VAX^{POS}PCR^{POS} group, and (I-K) VAX^{POS}PCR^{NEG} group, the relationship between an individual samples' inhibition value and cognate (C,F,H) IgM^{Spike} concentration. 975 (D.G.I) IaM^{Spike} 976 concentration, and (E,H,J) IgG^{Spike} concentration. Graph insets indicates the Multiple R-squared 977 value associated with the linear regression model of the respective data set (i.e. the % variation 978 in inhibition that can be explained by the indicated lg concentration), as well as its p-value (i.e. 979 the significance of the linear model as a whole).

980

Supplemental FIGURE S1. The CoV2 antigens and components relevant to our study. (A)
Depiction of CoV2 and its RNA genome, nucleocapsid (N, yellow) and Spike proteins, the latter
being differentially colored to indicate the Receptor Binding Domain (RBD, blue) and non-RBD
regions (green). (B) The amino acids which distinguish the CoV2^{Anc} Spike protein from CoV2^{US}
(also known as B.1.2), CoV2^{Alpha}, CoV2^{Gamma} and CoV2^{Delta}, as well as the Omicron lineages
CoV2^{O-BA.1}, CoV2^{O-BA.2}, CoV2^{O-BA.4} and CoV2^{O-BA.5}.

987

988 Supplemental FIGURE S2. The waves of COVID incidence in the counties surrounding our 989 university campuses. Daily COVID cases in the counties surrounding each campus of our 990 university, as reported by the Ohio Department of Health (ODH), for the period spanning Jan 2021 991 \rightarrow May 2022. Shown are the data for (A) Franklin County, which surrounds the OSU-Columbus 992 campus; (B) Licking County, which surrounds the OSU-Newark campus; (C) Richland County, 993 which surrounds the OSU-Mansfield campus; (D) Allen County, which surrounds the OSU-Lima 994 campus; (E) Marion County, which surrounds the OSU-Marion campus; and (F) Wayne County, 995 which surrounds the OSU-Wooster campus. Overlaid onto each graph are the dates which 996 correspond to the six COVID waves (W1-W6) that occurred in our campus community (see FIG 997 2).

998

Supplemental FIGURE S3. The age of individuals whose PCR^{Pos} saliva sample was viral
 genome sequenced. The age range of individuals whose saliva was PCR^{Pos} and sequenced
 throughout the monitoring period. Violin plots depicting the ages of individuals whose saliva was
 PCR^{Pos} and sequenced each month.

1003

1004 Supplemental FIGURE S4. The representation of each sex among individuals whose 1005 PCR^{POS} saliva met sequencing criteria. The percent of males, females and undefined sex 1006 among individuals whose saliva was PCR^{POS} and sequenced for lineage identification for each 1007 week of our study period, the criteria for sequencing being a $C_T \leq 33$. Overlaid onto the graph in 1008 gray are the periods corresponding to Waves 1-6 in our university community. The average values 1009 for each sex across the entire study period are indicated by the hatched lines.

1010

1011 Supplemental FIGURE S5. VOC Spike-specific Ig levels in the saliva of newly positive,

1012 asymptomatic individuals at the time of PCR testing. Saliva samples that were positive for

either the CoV2^{US}, CoV2^{Alpha}, CoV2^{Gamma} or CoV2^{Delta} lineage were used to measure the
concentrations of (A) IgM^{Spike}, (B) IgA^{Spike} and (C) IgG^{Spike}. Varying by column were the coating
antigens (Ag) used for each measurement, the Ag being recombinant forms of either the CoV^{Anc}
Spike (Column 1), CoV2^{Alpha} Spike (Column 2), CoV2^{Beta} Spike (Column 3), and CoV2^{Gamma} Spike
(Column 4). Antibody levels are expressed in arbitrary units of luminescence. Note that the CoV^{Anc}
-specific IgM, IgA and IgG values in (A-C) Column 1 were transformed into WHO Binding Antibody
Units (BAUs) for FIG 4.

1020

1021 Supplemental FIGURE S6. VOC Spike-specific Ig levels in saliva of CoV2^{Delta}-infected 1022 unvaccinated individuals, CoV2^{Delta}-infected vaccinees, and uninfected vaccinees. During and after COVID Wave 4 (i.e. that which was caused by CoV2^{Delta}), saliva from three groups of 1023 1024 individuals were collected and used for Ig measurements: those who had not been fully vaccinated and were positive for CoV2^{Delta} (Vax^{NEG} PCR^{POS}), those who had been fully vaccinated 1025 1026 and were positive for the CoV2^{Delta} (Vax^{POS} PCR^{POS}), and those who had been fully vaccinated and were negative for any CoV2 lineage (Vax^{POS} PCR^{NEG}). Shown for each individual in each 1027 aroup are the levels of (A) IgM^{Spike}, (B) IgA^{Spike} and (C) IgG^{Spike} which bind to four different coating 1028 antigens (Ag), the Ag being recombinant forms of either the CoV^{Anc} Spike (Column 1), CoV2^{Alpha} 1029 Spike (Column 2), CoV2^{Beta} Spike (Column 3), CoV2^{Gamma} Spike (Column 4) and CoV2^{Delta} Spike 1030 1031 (Column 5). Antibody levels are expressed in arbitrary units of luminescence. Note that the CoV^{Anc} 1032 -specific IgM, IgA and IgG values in (A-C) Column 1 were transformed into WHO Binding Antibody 1033 Units (BAUs) for FIG 6.



FIGURE 1



FIGURE 2



FIGURE 3





FIGURE 5





Α



FIGURE 7



Substitution (relative to Ancestral)

Deletion (relative to Ancestral)

S Insertion of EPE at postion 214 (Omicron BA.1 specific)

Supplemental FIGURE S1



Supplemental FIGURE S2



Supplemental FIGURE S3



Supplemental FIGURE S4



CoV2 lineage present in saliva





Supplemental FIGURE S5

medRxiv preprint doi: https://doi.org/10.1101/2023.01.30.23285195; this version posted February 1, 2023. The copyright holder for this preprint Coating (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. antigen: Cov2^{MME} Spike Cov



С

Α

Coating antigen: CoV2^{Anc} Spike CoV2^{Alpha} Spike CoV2^{Beta} Spike CoV2^{Gamma} Spike CoV2^{Detta} Spike 700





Supplemental FIGURE S6